Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$0.35
$0.03
$3.17
$3.50M0.497.01 million shs61.02 million shs
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$1.88
$1.89
$0.58
$5.87
$98.94M0.752.46 million shs169,314 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.51
+8.5%
$6.00
$3.85
$8.75
$603.10M1.24389,197 shs448,022 shs
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
$11.17
$11.15
$3.46
$19.00
$299.85M1.31212,171 shs330 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$4.98
+2.2%
$3.76
$2.41
$10.37
$385.69M2.341.19 million shs702,337 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
0.00%0.00%0.00%0.00%-94.38%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00%0.00%0.00%0.00%0.00%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+6.79%+5.81%+26.74%+12.89%+75.63%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
0.00%0.00%0.00%0.00%0.00%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+5.87%+2.74%+37.57%+43.24%-18.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/AN/AN/AN/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.5385 of 5 stars
3.52.00.04.83.72.50.6
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.4323 of 5 stars
4.62.00.00.02.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
2.50
Moderate Buy$2.17∞ Upside
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
0.00
N/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00219.79% Upside
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
0.00
N/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10203.46% Upside

Current Analyst Ratings Breakdown

Latest GRTS, JNCE, OYST, SLDB, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
5/14/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
5/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
$496K0.00N/AN/A$0.54 per share0.00
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
$82M1.21N/AN/A$3.54 per share0.53
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.12N/AN/A$0.87 per share8.63
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
$24.54M12.22N/AN/A$3.80 per share2.94
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M47.67N/AN/A$3.43 per share1.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A19.75N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)

Latest GRTS, JNCE, OYST, SLDB, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
N/AN/AN/AN/AN/A
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
1.83
2.54
2.54
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
N/A
8.37
8.37
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
8.49
3.35
3.11
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89

Institutional Ownership

CompanyInstitutional Ownership
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
48.46%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
80.66%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
96.70%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
4.61%
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
6.92%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
17.90%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gritstone bio, Inc. stock logo
GRTS
Gritstone bio
190108.57 million111.84 millionOptionable
Jounce Therapeutics, Inc. stock logo
JNCE
Jounce Therapeutics
13752.63 million48.99 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.36 million74.34 millionOptionable
Oyster Point Pharma, Inc. stock logo
OYST
Oyster Point Pharma
30326.84 million22.04 millionNot Optionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.51 million76.04 millionOptionable

Recent News About These Companies

Solid Biosciences Inc. (SLDB) - Yahoo Finance
SLDB - Solid Biosciences Inc Valuation - Morningstar
Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance
Brokers Offer Predictions for SLDB FY2026 Earnings
When Might Solid Biosciences Run Out Of Money?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Gritstone bio stock logo

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Jounce Therapeutics stock logo

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.50 +0.59 (+8.45%)
Closing price 02:41 PM Eastern
Extended Trading
$7.50 0.00 (0.00%)
As of 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Oyster Point Pharma stock logo

Oyster Point Pharma NASDAQ:OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$4.98 +0.11 (+2.18%)
Closing price 03:59 PM Eastern
Extended Trading
$5.03 +0.05 (+0.98%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.